AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Dividend stocks have been the backbone of market returns for over a century, contributing roughly two-thirds of total returns ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

Analysts are optimistic about AbbVie Inc.’s (NYSE:ABBV) growth, primarily because of its two blockbuster drugs, Skyrizi and Rinvoq. These drugs, which target dermatology, rheumatology ...

Humira sales in 2024 were $9 billion, down 58% from their peak. The good news is that AbbVie has already found a replacement ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Booking ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...